Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

Michael Rowe Biography and Net Worth

COO of Eyenovia

Michael Rowe has been serving as our Vice President, Commercial since October 2019 and, prior to that, since July 2018, as our Vice President, Marketing. From February 2016 to June 2018, Mr. Rowe was head of Global Strategic Marketing, Ophthalmology at Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), where he was responsible for the United States and international commercialization, planning and execution for Rhopressa®, for the lowering of elevated IOP in patients with open-angle glaucoma or ocular hypertension. Previously, he spent 12 years at Allergan plc (NYSE: AGN) in various roles supporting corporate strategic initiatives as well as strategic planning for the company’s worldwide glaucoma franchise, including the development of bimatoprost SR and the global launch of Ganfort® UD. Mr. Rowe also has held senior marketing roles at Bayer Healthcare Pharmaceuticals Inc., Women First HealthCare, Inc. (a former public company) and Pfizer Inc (NYSE: PFE). Mr. Rowe holds an M.Sc. in Human Factors/Experimental Psychology from Rensselaer Polytechnic Institute and a B.A. in Psychology from the State University of New York at Stony Brook.

What is Michael M. Rowe's net worth?: The estimated net worth of Michael M. Rowe is at least $18,788.15 as of December 4th, 2023. Mr. Rowe owns 32,927 shares of Eyenovia stock worth more than $18,788 as of April 19th. This net worth estimate does not reflect any other investments that Mr. Rowe may own. Additionally, Mr. Rowe receives an annual salary of $750,010.00 as COO at Eyenovia. Learn More about Michael M. Rowe's net worth.
How old is Michael M. Rowe?: Mr. Rowe is currently 62 years old. There are 3 older executives and no younger executives at Eyenovia. The oldest executive at Eyenovia is Mr. John P. Gandolfo CPA, CFO & Secretary, who is 63 years old. Learn More on Michael M. Rowe's age.
What is Michael M. Rowe's salary?: As the COO of Eyenovia, Inc., Mr. Rowe earns $750,010.00 per year. The highest earning executive at Eyenovia is Dr. Tsontcho Ianchulev M.D., M.P.H., MPH, Co-Founder & Executive Chairman, who commands a salary of $920,870.00 per year. Learn More on Michael M. Rowe's salary.
How do I contact Michael M. Rowe?: The corporate mailing address for Mr. Rowe and other Eyenovia executives is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. Eyenovia can also be reached via phone at (917) 289-1117 and via email at [email protected]. Learn More on Michael M. Rowe's contact information.
Has Michael M. Rowe been buying or selling shares of Eyenovia?: Michael M. Rowe has not been actively trading shares of Eyenovia in the last ninety days. Most recently, on Monday, December 4th, Michael M. Rowe bought 4,890 shares of Eyenovia stock. The stock was acquired at an average cost of $1.36 per share, with a total value of $6,650.40. Following the completion of the transaction, the chief executive officer now directly owns 32,927 shares of the company's stock, valued at $44,780.72. Learn More on Michael M. Rowe's trading history.
Who are Eyenovia's active insiders?: Eyenovia's insider roster includes Stuart Grant (Major Shareholder), Tsontcho Ianchulev (CEO), Kenneth Lee, Jr. (Director), Charles Mather, IV (Director), and Michael Rowe (COO). Learn More on Eyenovia's active insiders.
Are insiders buying or selling shares of Eyenovia?: In the last twelve months, Eyenovia insiders bought shares 13 times. They purchased a total of 323,711 shares worth more than $566,174.16. In the last twelve months, insiders at the sold shares 2 times. They sold a total of 150,000 shares worth more than $795,000.00. The most recent insider tranaction occured on March, 28th when Major Shareholder Stuart M Grant bought 100,000 shares worth more than $98,000.00. Insiders at Eyenovia own 7.8% of the company. Learn More about insider trades at Eyenovia.
Information on this page was last updated on 3/28/2024.

Michael M. Rowe Insider Trading History at Eyenovia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/4/2023	Buy	4,890	$1.36	$6,650.40	32,927
9/19/2023	Buy	1,400	$1.66	$2,324.00	28,037
9/15/2023	Buy	1,137	$1.75	$1,989.75	26,637
10/27/2021	Buy	1,200	$4.14	$4,968.00
9/13/2021	Buy	1,500	$4.40	$6,600.00	4,300
5/27/2021	Buy	1,400	$4.71	$6,594.00	2,800
9/25/2018	Buy	800	$4.23	$3,384.00

Michael M. Rowe Buying and Selling Activity at Eyenovia

Eyenovia Company Overview

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Today's Range

Now: $0.57

$0.52

$0.59

50 Day Range

MA: $1.34

$0.53

$2.37

2 Week Range

Now: $0.57

$0.50

$5.85

Volume

1,370,109 shs

Average Volume

1,041,073 shs

Market Capitalization

$27.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64

Secret Bull Market Starts in This Unusual Sector

From Altimetry | Ad

Click for my No. 1 investment, all free of charge, click here.

Michael Rowe Biography and Net Worth

What is Michael M. Rowe's net worth?

How old is Michael M. Rowe?

What is Michael M. Rowe's salary?

How do I contact Michael M. Rowe?

Has Michael M. Rowe been buying or selling shares of Eyenovia?

Who are Eyenovia's active insiders?

Are insiders buying or selling shares of Eyenovia?